Other

Canon Kabushiki Kaisha

Fujifilm Corporation

Kyoto University

Ono Pharmaceutical Co., Ltd.

Nof Corporation

Kaken Pharmaceutical Company, Ltd.

Konica Minolta, Inc.

Nitto-denko Corporation

Ajinomoto Co., Ltd.

Sanyo Chemical Industries, Ltd.

Denka Company Limited

Santen Pharmaceutical Co., Ltd.

Senju Pharmaceutical Co., Ltd.

Kaneka Corporation

Yasuhiko Tabata

Tetsuya Yano

Takeshi Miyazaki

Satoshi Yuasa

Kohei Watanabe

Masato Minami

Taichi Shintou

Tsuyoshi Nomoto

Yoshinori Tomida

Kentaro Nakamura

Sachiko Yamauchi

Jun-ichiro Jo

Mie Morita

Kenji Fujii

Hiroaki Takahashi

Akihiro Maezawa

Hiroaki Matsubara

Makoto Mochizuki

Shigeru Kinoshita

Noriko Koizumi

Yuji Sakamoto

Shigeo Furuyoshi

Manabu Kitazawa

Naoki Okumura

Masamichi Hashimoto

Yoko Masuzawa

Akihiko Saito

Jun Yamashita

Satoru Ohashi

Chie Inui

Shinji Tanaka

Akio Ohno

Kiyoshi Ando

Shingo Kawabata

Natsumi Hirayama

Kenji Yamashita

Kohei Yoshimura

Takafumi Imaizumi

Mie Okano

Fumihiko Kitagawa

Mayuko Kishi

Miyuki Sato

Hiromi Sakamoto

Hidemasa Oh

Masaaki Ii

Fumiyo Koide

Masashi Komeda

Eri Sanda

Mika Yamagata

Hiroshi Kohara

Kousaku Ohkawa

Shinichi Okamoto

Shunsuke Takei

Itsuki Yamamoto

Naofumi Takehara

Tomohiko Asahara

Koji Sakaguchi

Masaaki Il

Susumu Miyamoto

Yoshiro Ikada

Hidezo Mori

Etsuro Tanaka

Takehiko Matsuo

Harukazu Iseki

Naoto Fukuyama

Hirofumi Kasahara

Saburo Sone

Mayumi Seto

Fumitake Gejyo

The present invention addresses the problem of providing: a hydrogel particle which can be taken into a cell by the action of the cell and can control the release of a magnetic particle enclosed therein into the cell so as to retain the magnetic particle in the cell for a long period; a method for producing the hydrogel particle; a cell or a cell structure each enclosing the hydrogel particle therein; and a method for evaluating the activity of a cell using the hydrogel particle. The present invention solves the problem by a hydrogel particle including: a domain which is composed of a first hydrogel; a matrix which encloses the domain and is composed of a second hydrogel having a different crosslinking degree or composition from that of the first hydrogel; and a magnetic particle which is supported by at least the first hydrogel.

Hydrogel particle and method for producing same, cell or cell structure each enclosing hydrogel particle therein, method for evaluating activity of cell using hydrogel particle, and use of hydrogel particle as sustained release preparation

A statin-encapsulated nanoparticle contains a bioabsorbable polymer and statin encapsulated in the nanoparticle. Suitable bioabsorbable polymers include a polylactic acid (PLA) polymer or a polylactic acid-glycolic acid (PLGA) copolymer. The statin-encapsulated nanoparticle can be used to enhance the function of a stem cell. The stem cell can be a stem cell for treating an inflammatory disease.

Statin-containing nanoparticle preparation for enhancing function of stem cells for treating inflammatory disease, and functionally enhanced stem cells containing same for treating inflammatory disease

Provided is an agent for preserving a biological component, comprising a hydrogel, the hydrogel comprising a crosslinked product formed from a compound having a plurality of hydroxyl groups and a modified hyaluronic acid having substituents capable of reacting with the hydroxyl groups to form a crosslinked structure.

Agent for preserving biological component

A preparation containing a statin-encapsulated nanoparticle obtained by encapsulating statin in a nanoparticle containing a bioabsorbable polymer is disclosed. The nanoparticle has a number average particle diameter of less than 1000 nm. The preparation is used to enhance the function of a stem cell. A stem cell with an enhanced function is disclosed. The stem cell takes up and contains the statin-encapsulated nanoparticle.

Statin-encapsulated nanoparticle preparation for enhancing stem cell function, stem cell with enhanced function containing statin-encapsulated nanoparticle, and method for producing same

The present invention relates to layered cell sheets comprising living cells and methods for producing the same. Specifically, the present invention provides methods for layering cell sheets, comprising layering cell sheets using hydrogel or preferably gelatin hydrogel. The present invention also provides layered cell sheets produced by such methods, and pharmaceutical compositions or therapeutic agents comprising layered cell sheets.

Layered cell sheet incorporating hydrogel

The invention provides a cell mobilizing agent capable of efficiently and continuously accumulating cells involved in tissue repair. In particular, the cell mobilizing agent contains a lysophospholipid introduced with retinoic acid represented by the formula (1) and/or the formula (2) or a physiologically acceptable salt thereof as an active ingredient: wherein Rand Rare each a retinoyl group or hydrogen and are not the same.

Cell mobilization agent containing lysophospholipid with retinoic acid introduced

An object of the present invention is to provide an identification method for a macrophage subtype using an organic compound. Another object of the present invention is to provide a macrophage identification agent containing an organic compound in which a spectral characteristic obtained when the organic compound is added is different depending on a macrophage subtype. Still another object of the present invention is to provide an evaluation method for a macrophage subtype using a macrophage identification agent, an analysis method for correlation between a macrophage subtype and a test substance, a screening method for correlation between a macrophage subtype and a test substance, and a kit. An identification method for a macrophage subtype utilizing that a spectral characteristic obtained with an organic compound added is different depending on a macrophage subtype is provided.

Macrophage identification agent, and identification method, sorting method, evaluation method, screening method and kit using the macrophage identifier agent

An object of the present invention is to provide a cell-adhesive material for biological tissues, in which the surface of a material for biological tissues (particularly metallic material) is modified strongly with a large amount of a cell-adhesive artificial peptide (P) that retains a biological activity. The present invention provides a cell-adhesive material for biological tissues including a cell-adhesive artificial peptide (P) and a material for biological tissues, wherein the cell-adhesive artificial peptide (P) is immobilized on the surface of the material for biological tissues through an electrochemical reaction. The cell-adhesive artificial peptide (P) is preferably a peptide (P1) that is synthesized by a genetic recombinant microorganism and has at least one cell-adhesive minimal amino acid sequence (X) in one molecule. The number of the cell-adhesive minimal amino acid sequences (X) in one molecule of the polypeptide (P1) is preferably 3 to 50.

Cell adhesive material for biological tissue

An iron oxide particle constituting a Resovist (trademark) absorbs a small quantity of light in a near infrared region and emits a weak photoacoustic signal. According to a particle having a catechol-like compound and iron atoms, the particle having a ratio of the number of moles of the catechol-like compound to the number of moles of the iron atoms of 270/10,000 or more, light absorption in the near infrared region increases and a strong photoacoustic signal can be transmitted.

Particle and photoacoustic contrast agent having the particle

An object of the present invention is to provide a kidney-imaging agent which is composed of bioabsorbable materials, transiently accumulates in a kidney for a short period of time, and does not remain in the kidney for a prolonged time after accumulation. The present invention provides a kidney-imaging agent which comprises a gelatin-like protein.

Kidney-imaging agent comprising recombinant gelatin

The present invention provides a hematopoietic stem cell identification probe. A hematopoietic stem cell analysis probe containing, as an active ingredient, one or more compounds represented by the general formula (1) has been developed: 

Hematopoietic stem cell identification probe

The present invention aims to provide a medical material which is safe for the live body, has high biocompatibility and is useful for promotion of cell differentiation. The present invention produces a medical material for promoting cell differentiation, which contains polyamino acid as a main component, wherein the polyamino acid contains at least one kind of amino acid residue selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a glycine residue, a glutamine residue, an aspartic acid residue optionally containing a protecting group in the side chain, a tyrosine residue optionally containing a protecting group in the side chain, a tryptophan residue optionally containing a protecting group in the side chain, a lysine residue optionally containing a protecting group in the side chain, and a glutamic acid residue optionally containing a protecting group in the side chain.

Medical material and method for manufacturing same

There is provided a gelatin-ICG complex that can suppress leakage of ICG included therein. The complex has a gelatin derivative including at least one of a phospholipid covalently bonded to a gelatin or a cholesterol covalently bonded to a gelatin, and indocyanine green.

Complex and contrast agent for photoimaging using the same

An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.

Sustained release composition containing SDF-1

The present invention relates to a material for induction of hard tissue regeneration, comprising platelet-rich plasma and gelatin &#x3b2;-TCP sponge, which promotes angiogenesis, osteogenesis, chondrogenesis and the like.

Material for induction of hard tissue regeneration

Growing community of inventors

Kyoto, Japan

Yasuhiko Tabata